Novonodisc is expected to change the market for type 2 diabetes treatment as GLP-1 similarity products are released one after another. Novonodisc received domestic approval for Rybelsus (Semaglutide) on the 2nd following Ozempic on the 28th of last month. Ozempic is a long-lasting injection administered once a week, and Rybelsus is a drug that has changed it to an oral drug.

Ozempic is expected to emerge as a strong competitive drug for Eli Lilly Trulicity, which currently dominates the GLP-1 analog market. Trulicity is a injection once a week that monopolizes the GLP-1 similarity market worth 50 billion won in Korea. According to IQVIA, a pharmaceutical market research firm, Trulicity posted 49.9 billi